Q2 Revenue Up 19% but Loss Widens to $3.37M; Mexico Patent Secured
BIAF is trading near its 52-week low of $0.507 (0.3% above the low).
Summary
bioAffinity reported Q2 revenue of $1.51M, a 19% YoY increase, but the net loss widened to $3.37M, or $0.64 per share. The company also received a Mexican patent allowance for its sputum-based lung cancer test, strengthening its IP. This follows the recent 10-Q filing that disclosed a going concern warning and a cash runway ending this month. The growing losses and imminent cash crunch overshadow the revenue growth and patent progress. The stock trades near its 52-week low of $0.507, reflecting severe financial distress.
At the time of this announcement, BIAF was trading at $0.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $0.51 to $13.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.